Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LFG316 in active non-infectious uveitis
NCT01526889Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2012
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of tesidolumab in non-infectious intermediate uveitis, Posterior uveitis (non-infectious), non-infectious panuveitis (NIU), sponsored by Novartis. Started Dec 2012; status: completed.
02
Drugs
tesidolumab
03
Conditions
non-infectious intermediate uveitisPosterior uveitis (non-infectious)non-infectious panuveitis (NIU)
Beyond the preview
Go deeper on NCT01526889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01526889.